title: Miscellaneous adverse events with biologic agents (excludes infection and malignancy).
abstract: Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration-approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.
authors.affiliation: Division of Gastroenterology, Department of Medicine, Center for Inflammatory Bowel Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Rabb 425, Boston, MA 02215, USA.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Feuerstein
authors.affiliation: Division of Gastroenterology, Department of Medicine, Center for Inflammatory Bowel Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Rabb 425, Boston, MA 02215, USA. Electronic address: acheifet@bidmc.harvard.edu.
authors.forename: Adam S
authors.initials: AS
authors.lastname: Cheifetz
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000628:therapy; D001688:Biological Products / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D006331:Heart Diseases / Q000139:chemically induced; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D007262:Infusions, Intravenous; D008171:Lung Diseases / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D012871:Skin Diseases / Q000139:chemically induced* / Q000628:therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D001688:Biological Products; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Adalimumab; Anti-tumor necrosis factor; Autoimmune disease; Certolizumab pegol; Complications; Golimumab; Infliximab; Infusion reactions